GW-405,833
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.162.054 |
| Chemical and physical data | |
| Formula | C23H24Cl2N2O3 |
| Molar mass | 447.36 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
GW-405,833 (L-768,242) is a drug that acts as a potent and selective partial agonist for the cannabinoid receptor subtype CB2, with an EC50 of 0.65 nM and selectivity of around 1200x for CB2 over CB1 receptors.[1][2] Animal studies have shown it to possess antiinflammatory and anti-hyperalgesic effects at low doses, followed by ataxia and analgesic effects when the dose is increased.[3][4] Selective CB2 agonist drugs such as GW-405,833 are hoped to be particularly useful in the treatment of allodynia and neuropathic pain for which current treatment options are often inadequate.[5][6]
References
[edit]- ^ Huffman JW (September 2000). "The search for selective ligands for the CB2 receptor". Current Pharmaceutical Design. 6 (13): 1323–37. doi:10.2174/1381612003399347. PMID 10903395.
- ^ Marriott KS, Huffman JW (2008). "Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor". Current Topics in Medicinal Chemistry. 8 (3): 187–204. doi:10.2174/156802608783498014. PMID 18289088.
- ^ Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT (April 2002). "CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain". Pain. 96 (3): 253–60. doi:10.1016/s0304-3959(01)00454-7. PMID 11972997. S2CID 24816928.
- ^ Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, et al. (April 2005). "Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy". Neuropharmacology. 48 (5): 658–72. doi:10.1016/j.neuropharm.2004.12.008. PMID 15814101. S2CID 10121434.
- ^ Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, Reggiani A (March 2006). "CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms". The European Journal of Neuroscience. 23 (6): 1530–8. doi:10.1111/j.1460-9568.2006.04684.x. PMID 16553616. S2CID 19266396.
- ^ Leichsenring A, Andriske M, Bäcker I, Stichel CC, Lübbert H (June 2009). "Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain". Naunyn-Schmiedeberg's Archives of Pharmacology. 379 (6): 627–36. doi:10.1007/s00210-008-0386-4. PMID 19152053. S2CID 25085194.
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |